These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8176760)

  • 1. Differential accumulation of gangliosides by the brains of MPTP-lesioned mice.
    Saulino MF; Schengrund CL
    J Neurosci Res; 1994 Feb; 37(3):384-91. PubMed ID: 8176760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
    Schneider JS; Kean A; DiStefano L
    J Neurosci Res; 1995 Sep; 42(1):117-23. PubMed ID: 8531220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
    Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK
    Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain.
    Oida Y; Kitaichi K; Nakayama H; Ito Y; Fujimoto Y; Shimazawa M; Nagai H; Hara H
    Brain Res; 2006 Apr; 1082(1):196-204. PubMed ID: 16515773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
    Schmidt N; Ferger B
    Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions.
    Fornai F; Alessandrì MG; Torracca MT; Bassi L; Corsini GU
    J Pharmacol Exp Ther; 1997 Oct; 283(1):100-7. PubMed ID: 9336313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
    Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
    Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
    Pope-Coleman A; Tinker JP; Schneider JS
    Synapse; 2000 May; 36(2):120-8. PubMed ID: 10767059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2'-NH(2)-MPTP [1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] depletes serotonin and norepinephrine in rats: a comparison with 2'-CH(3)-MPTP [1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine].
    Unger EL; Mazzola-Pomietto P; Murphy DL; Andrews AM
    J Pharmacol Exp Ther; 2002 Nov; 303(2):527-33. PubMed ID: 12388632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
    Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does melatonin help save dopaminergic cells in MPTP-treated mice?
    Ma J; Shaw VE; Mitrofanis J
    Parkinsonism Relat Disord; 2009 May; 15(4):307-14. PubMed ID: 18793863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact.
    Lau YS; Novikova L; Roels C
    Neurosci Res; 2005 Aug; 52(4):371-8. PubMed ID: 15936837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of the damaged dopamine system to GM1 and semisynthetic gangliosides: effects of dose and extent of lesion.
    Schneider JS; Distefano L
    Neuropharmacology; 1995 May; 34(5):489-93. PubMed ID: 7566482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization.
    Shen YQ; Hebert G; Lin LY; Luo YL; Moze E; Li KS; Neveu PJ
    J Neuroimmunol; 2005 Jan; 158(1-2):14-25. PubMed ID: 15589033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
    Zuddas A; Fascetti F; Corsini GU; Piccardi MP
    Exp Neurol; 1994 May; 127(1):54-61. PubMed ID: 8200437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys.
    Wallace BA; Ashkan K; Heise CE; Foote KD; Torres N; Mitrofanis J; Benabid AL
    Brain; 2007 Aug; 130(Pt 8):2129-45. PubMed ID: 17584773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoro-Jade C can specifically stain the degenerative neurons in the substantia nigra of the 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine-treated C57BL/6 mice.
    Bian GL; Wei LC; Shi M; Wang YQ; Cao R; Chen LW
    Brain Res; 2007 May; 1150():55-61. PubMed ID: 17397812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.